BioVie has completed enrollment in its Phase 2 SUNRISE-PD study evaluating bezisterim in early Parkinson’s disease. The trial has enrolled 60 patients diagnosed within the past four years who have not yet initiated levodopa therapy, reaching full capacity ahead of schedule. This achievement positions the company to report key safety and exploratory efficacy data later this year, a critical inflection point for investors assessing bezisterim’s potential to slow disease progression and capture market share in a high‐unmet‐need patient population.

BioVie shares declined 4.7% during the latest trading session, on volume of approximately 79,600 shares—a 35% drop from its 30‐day average. The company’s market capitalization stands at $9.12 million, reflecting investor caution around near‐term financing and development milestones. With a trailing price‐to‐earnings ratio of -0.17 and a beta of 0.36, the stock exhibits low market correlation but underscores ongoing operating losses as BioVie advances its clinical programs.

Research firms have offered divergent views: one analyst upgraded BioVie from sell to hold, while another maintains a sell rating, resulting in a consensus Moderate Buy assessment. On the institutional front, several hedge funds established new positions in the third quarter, including Prelude Capital Management and Prosperity Wealth Management, allocating roughly $275,000 and $273,000 respectively. Overall, institutional ownership accounts for 4.6% of outstanding shares, signaling measured confidence as BioVie approaches pivotal data readouts.